Skip to content

Study · Not a test of the peptide alone · 2005

3 results

Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

Erickson D, Keenan DM, Farhy L, Mielke K, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism21 Dec 2004Cited by 19 (Europe PMC)

PMID15613434 (opens in a new tab)PMCIDPMC1236972 (opens in a new tab)DOI10.1210/jc.2004-1621 (opens in a new tab)PepBankPUB-15613434
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In premenopausal women, the estradiol-clamped state raised maximal GH stimulation by paired l-arginine and GHRP‑2 compared with placebo.

    In plain wordsIn premenopausal women, estradiol raised the peak GH response to an l-arginine and GHRP‑2 combination compared with placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseMaximal l-arginine/GHRP-2 stimulation of GH under estradiol
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    maximal stimulation by paired l-arginine/GH-releasing peptide (GHRP)-2 (P = 0.028).
    1 context sentence
    Summary · context
    To this end, 13 women underwent GnRH agonist-induced gonadal down-regulation followed by graded transdermal addback of E(2) or Pl and randomly ordered iv infusions of saline or paired secretagogues on separate morning fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In premenopausal women, estradiol accelerated the initial GH release induced by GHRH plus GHRP‑2 compared with placebo.

    In plain wordsIn premenopausal women, estradiol sped up the first GH release caused by a GHRH and GHRP‑2 combination compared with placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseSpeed of initial GH release induced by GHRH/GHRP-2 under estradiol
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    E(2) also markedly accelerated the initial release of GH induced by GHRH/GHRP-2 (P < 0.001)
    1 context sentence
    Summary · context
    To this end, 13 women underwent GnRH agonist-induced gonadal down-regulation followed by graded transdermal addback of E(2) or Pl and randomly ordered iv infusions of saline or paired secretagogues on separate morning fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In premenopausal women, estradiol concentrations positively predicted 41% of the variability in GH secretion stimulated by l-arginine plus GHRP‑2.

    In plain wordsIn premenopausal women, higher estradiol was linked to a stronger GH response to an l-arginine and GHRP‑2 combination.

    Peptide
    GHRP-2
    Outcome
    IncreaseEstradiol as predictor of l-arginine/GHRP-2-stimulated GH secretion
    Study

    n = 13

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Variability in GH secretion predicted by estradiol
    41%
    l-arginine/GHRP-2

    Source sentences

    Summary
    E(2) concentrations positively forecast 41% of intersubject variability in GH secretion stimulated by combined l-arginine/GHRP-2 (P = 0.018)
    1 context sentence
    Summary · context
    To this end, 13 women underwent GnRH agonist-induced gonadal down-regulation followed by graded transdermal addback of E(2) or Pl and randomly ordered iv infusions of saline or paired secretagogues on separate morning fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.